9.25
+0.01 (+0.11%)
At close: Aug 27, 2021
9.26
+0.01 (+0.11%)
After Hours: 8/27/2021, 8:19:13 PM
Taking everything into account, KIN scores 2 out of 10 in our fundamental rating. KIN was compared to 525 industry peers in the Biotechnology industry. KIN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. KIN has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- In the past year KIN has reported negative net income.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.53% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | -500.9% | ||
| PM (TTM) | -529.26% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- There is no outstanding debt for KIN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- KIN has an Altman-Z score of 4.83. This indicates that KIN is financially healthy and has little risk of bankruptcy at the moment.
- KIN has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.19 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.83 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 7.02 indicates that KIN has no problem at all paying its short term obligations.
- KIN has a Quick Ratio of 7.02. This indicates that KIN is financially healthy and has no problem in meeting its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.02 | ||
| Quick Ratio | 7.02 |
3. Growth
3.1 Past
- The earnings per share for KIN have decreased strongly by -53.73% in the last year.
- KIN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -81.43%.
EPS 1Y (TTM)-53.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-130.77%
Revenue 1Y (TTM)-81.43%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-91.06%
3.2 Future
- Based on estimates for the next years, KIN will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.40% on average per year.
- The Revenue is expected to grow by 20.46% on average over the next years. This is a very strong growth
EPS Next Y-51.22%
EPS Next 2Y36%
EPS Next 3Y15.8%
EPS Next 5Y12.4%
Revenue Next Year-49.68%
Revenue Next 2Y-1.59%
Revenue Next 3Y3.21%
Revenue Next 5Y20.46%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for KIN. In the last year negative earnings were reported.
- Also next year KIN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | -10.71 |
4.3 Compensation for Growth
- A more expensive valuation may be justified as KIN's earnings are expected to grow with 15.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36%
EPS Next 3Y15.8%
5. Dividend
5.1 Amount
- KIN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Kindred Biosciences / KIN FAQ
Can you provide the ChartMill fundamental rating for Kindred Biosciences?
ChartMill assigns a fundamental rating of 3 / 10 to KIN.
Can you provide the valuation status for Kindred Biosciences?
ChartMill assigns a valuation rating of 1 / 10 to Kindred Biosciences (KIN). This can be considered as Overvalued.
What is the profitability of KIN stock?
Kindred Biosciences (KIN) has a profitability rating of 1 / 10.
How sustainable is the dividend of Kindred Biosciences (KIN) stock?
The dividend rating of Kindred Biosciences (KIN) is 0 / 10 and the dividend payout ratio is 0%.